EHC 2022 | The efficacy of symptomatic treatments in children and adolescents with chronic migraine

Chronic migraine affects from 0.6% to 1.8% of children and adolescents and decreases their quality of life. Massimiliano Valeriani, MD, PhD, Hospital Bambino Gesù, Rome, Italy, discusses the results of a study analyzing the type of symptomatic drugs used and their efficacy for the treatment of acute migraine attacks in pediatric patients with chronic migraine. Findings have shown that the drugs used for acute attacks are not very effective in patients with chronic migraine and that some patients do not respond to any acute treatment. This interview took place at the 16th European Headache Congress (EHC) in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.